Φορτώνει......
Upregulation of CIP2A in estrogen depletion‐resistant breast cancer cells treated with low‐dose everolimus
Everolimus (EVE), an inhibitor of mammalian target of rapamycin, is an emerging second‐line therapeutic option for hormone therapy‐resistant breast cancers. However, some patients do not respond to EVE, whereas in others it exacerbates the disease. Cellular inhibitor of protein phosphatase 2A (CIP2A...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | FEBS Open Bio |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
John Wiley and Sons Inc.
2020
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7530388/ https://ncbi.nlm.nih.gov/pubmed/32810922 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/2211-5463.12956 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|